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Summary 
We report  a  soluble  isoform of mouse  Fas,  which is generated by alternative  splicing of Fas 
mRNA  to a newly identified exon located between exons 2 and 3 of the previously published 
Fas sequence. This splicing event creates a novel Fas transcript,  Fas [3, with the potential to en- 
code a truncated form of the extracellular domain, termed Fas B. In vitro, P815 mastocytoma 
cells transfected with Fas B become resistant to Fas ligand-induced apoptosis, and the resistance 
is mediated by a secreted product of the transfected cells.  In vivo, Fas  [3 mRNA  expression is 
correlated inversely with apoptosis among subsets of intrahepatic T  lymphocytes, a cell popula- 
tion in which activation-induced T  cell apoptosis occurs. We propose that Fas B  is a new cy- 
tokine that acts physiologically to limit apoptosis induced by Fas ligand. 
S 
oluble isoforms of cell surface receptors regulate recep- 
tor  function  in  a  number  of biological  systems.  Such 
soluble receptors most commonly retain ligand-binding ac- 
tivity  and  compete  for  ligand,  thus  inhibiting  receptor 
function (1-3). Soluble receptor isoforms may be generated 
by proteolytic cleavage of the  transmembrane  form or by 
alternative  mRNA  splicing to generate  distinct  molecular 
species.  In this report, we describe a soluble inhibitory iso- 
form of the CD95/Fas molecule, which is generated by al- 
ternative  splicing  and  is  differentially  expressed  in  T  cell 
subsets undergoing apoptosis in vivo. 
The  Fas  antigen  (CD95)  is  important  in  activation- 
induced  cell  death  of T  lymphocytes (4,  5)  and  is widely 
expressed  in the immune  system and in nonlymphoid tis- 
sues  (6,  7).  The susceptibility of cells  to apoptosis induced 
by Fas ligation is regulated not only through the density of 
Fas  on the  cell surface, but also by other mechanisms that 
are  poorly understood  (8-10).  We  have  cloned  a  variant 
Fas transcript that encodes a truncated,  soluble isoform that 
we  term  Fas B.  Expression  of Fas B  inhibits  apoptosis in- 
duced by Fas-Fas ligand (FasL) ~ interaction, and the differ- 
ential expression of the two Fas isoforms in vivo is consis- 
tent  with  a  role  in  controlling  apoptosis  in  a  subset  of 
activated T  cells  in the liver. 
Materials and Methods 
Reverse  Transcription (R T) PCR,  Cloning,  and Sequencing.  Mu- 
rine Fas message was amplified by PCR from total thymus cDNA 
1 Abbreviations used in this paper: Etn, early transposable element; FasL, Fas 
ligand; IHL, intrahepatic T lymphocyte; RT, reverse transcription. 
using primers F1  (CGGGGATCCACCATGCTGTGGATCTGG- 
GCTG)  and  RL1  (GCGGAATTCGATATCACTCCAGACA- 
TTGTCC).  Reactions contained 2.0 mM MgC12 and were run 
for 30 cycles of 1 min at 94~  1 min at  58~  and 1.5 rain at 
72~  The two resulting  products were separated  by agarose gel 
electrophoresis,  cloned into  pBluescript,  and sequenced  by the 
Taq-Dye-deoxy termination method, k-phage genomic clones of 
fas were isolated  as described  (11),  using a probe encoding the 
extracellular  domain published for murine  Fas  (115  to 558 bp) 
(6). The intronic regions surrounding exon 2A were sequenced 
from three  of these  clones  using the  exon 2A-specific primers 
2AFOR (CGGGCGGCCGCGGACCAGTCTGATTCCTGG- 
CCACG)  and  2AR  (GCGGCGGCCGCCTGCCTGCAAGA- 
TGTGCAGG). 
Antibodies  and Flow Cytometry.  The following antibodies  were 
used:  H57-597-Cy Chrome  (anti-TCR  CI~; Pharmingen,  San 
Diego, CA) (12); RA3-3A1-FITC (TIB-146, anti-B220;  kind gift 
fi:om Kim  Bottomly,  Yale  University,  New  Haven,  CT)  (13); 
H129-19-FITC (anti-CD4; Gibco BRL, Gaithersburg,  MD)  (14); 
53-6.7-Red  613  (anti-CD8ot;  Gibco  BILL)  (15);  and Jo-2-PE 
(anti-Fas;  Pharmingen)  (16). FACS  |  staining  was  performed  as 
described  (17).  Data were acquired with a FACScan  |  flow cy- 
tometer,  using FACScan  |  research  software,  and analyzed using 
Lysys  1.7  (instrument  and  software  from Becton Dickinson  & 
Co., Mountain View, CA). 
Transfection.  Fas B  cDNA was  obtained by RT-PCR using 
primers  F1  and  X3REV  (GCGGCGGCCGCATGGGGCA- 
CAGGTTGGTG),  digested  with  XbaI  and  SacI,  then  cloned 
into the same  sites of the pSRot-72(N.1)  eukaryotic expression 
vector.  The pSRot-72(N.1)  vector drives  expression  of the  in- 
serted  sequence under control of the SV40 early promoter and 
the HTLV I 5'  enhancer.  The integrity of the insert  was  con- 
firmed by sequencing as discussed  earlier,  and the vector DNA 
was electroporated into P815 cells as described (18). From >700 
neomycin-resistant clones,  200 were tested by PCR for presence 
of the cDNA insert.  Of several dozen positive  clones,  four were 
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Fas A, but different levels of Fas B, as tested by RT-PCR. 
A FasL expression  vector was made using the pSRot-72(N.1) 
vector and the FasL PCR product as described  earlier for Fas B 
using primers FASLIGF1 (GCCTCTAGAGCCACCATGCAG- 
CAGCCCATG)  and  FASLIGR4  (GCGGAGCTCTTTTAA- 
AGCTTATACAAGC) (125 to 965 bp in Takahashi  et al. [19]). 
This vector was transfected into NIH-3T3 cells by using calcium 
phosphate  precipitation as described  (18). Parallel to this transfec- 
tion, NIH-3T3 cells were also transfected with the empty pSRot- 
72(N.1)  vector,  and all transfected 3T3 cells were selected in 0.5 
mg/ml G418-supplemented medium. G418-resistant  clones were 
tested  for  FasL expression  by their  ability  to  differentially  kill 
wild-type but not lpr thymocytes.  One clone was selected for ex- 
pansion and use in further studies. All transfected  cells were ex- 
panded and maintained in 0.5  mg/ml G418-supplemented me- 
dium until the passage before their use in experiments. 
Isolation of  lntrahepatic Lymphocytes.  Intrahepatic  T  lymphocytes 
(IHLs) were isolated from livers of C57B1/6  mice by collagenase 
1V digestion and metrizamide flotation as described (20). 
RNase Protection Analysis.  Uniformly labeled  riboprobes  for 
RNase protection were synthesized as described  (11) at two dif- 
ferent specific  activities.  A  y-actin-specific probe,  which pro- 
tected a 105-bp fragment from the 3' untranslated region of the 
message, was synthesized  using 800  fxM cold rCTP and 25  IzM 
UTP, of which 5 I-tM was supplied as ~-[32p]UTP. A Fas-specific 
probe,  which  protected  a  121-bp  fragment from  Fas oL  and a 
272-bp band from Fas [3,  was synthesized  using 9  I~M each  of 
rCTP and UTP, of which 5  ~M was supplied  as c~-[32p]rCTP 
and o~-[32p]UTP. Protected fragments were separated by electro- 
phoresis  through  a  5%  polyacrylamide/8 M  urea  gel,  and the 
dried gel was exposed  to a phosphor-imaging screen  for 4-6 d. 
Under the  conditions used,  the  protected  fragments  frequently 
ran as doublet bands. In these cases, both bands were included in 
quantitation. The  specific signal from each  protected  Fas  band 
was divided by 1% of the specific signal from y-actin in that sam- 
ple to determine Fas message intensity in "actin units." 
Results 
Cloning and Sequence of Fas B.  In an RT-PCR  analysis 
of mouse Fas expression in thymocyte subsets, an amplified 
product of the expected size was consistently accompanied 
by a larger fragment that resulted from an alternative tran- 
script of the Fas gene. The alternative transcript (which we 
term  Fas  ~3)  arose  from  a  158-bp  insertion between  the 
second and  third  exons  of the  reported  Fas  sequence.  A 
K-phage mouse genomic DNA library was screened with a 
plasmid containing the  extracellular domain of the Fas se- 
quence, and three clones were isolated in which the novel 
sequence could be detected by PCR. The sequence of this 
insertion, which we term exon 2A, and its surrounding in- 
tronic splice signals are shown in Fig. 1 A. The incorpora- 
tion of exon 2A caused a frame shift in exon 3 of the gene, 
leading to a stop codon 27 bp into exon 3.  The translated 
product of this message,  Fas  B,  would be a  truncated Fas 
protein  containing a  single  cysteine-rich subdomain fol- 
lowed by a highly charged COOH-terminal tail. The ma- 
ture Fas B polypeptide has a predicted molecular mass of 11 
kD, with two potential N-linked glycosylation sites as well 
as O-linked sites. 
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Figure  1.  (A)  Genomic sequence of Fas exon 2A and flanking se- 
quences. The  158-bp nucleotide sequence of exon 2A and its flanking 
sequences in genomic DNA are shown. The interpolation  of exon 2A se- 
quence results in a frameshift and premature stop codon 27 bp into exon 
3.  The Fas 13 RNA therefore encodes a soluble protein, Fas B, corre- 
sponding to a single  subdomain  of the extracellular  domain of CD95/Fas. 
(B) Diagram ofexon 2A and surrounding  region. The relative  positions  of 
exon 2A and the Em insertion in lpr in the genomic Fas sequence are 
shown. The positions  were determined by RT-PCR using cDNA from 
Ipr and wild-type mice. 
Mutant lpr mice lack functional Fas expression because of 
the insertion ofa retroviral early transposable element (Etn) 
into this same region of the  Fas  gene  (21,  22).  To deter- 
mine the relationship ofexon 2A to the Etn insertion in lpr, 
we performed RT-PCR for Fas using cDNA from C57BI/6 
mice  or  congenic  B6-1pr  thymocytes.  Identical products 
were obtained from either template from reactions with a 
forward primer in exon 1 and a reverse primer in exon 2A. 
When reactions  contained a  forward  primer  in  exon  2A 
and a reverse primer in exon 3 or at the 3' end of the cod- 
ing region,  however,  we  observed  amplimers of the  ex- 
pected size only from the  C57B1/6  template. No product 
was seen from the B6-1pr template. Similar results were ob- 
tained for MRL.MP- + / +  and MRL.MP-Ipr/Ipr  template. 
Because  Fas  RNA  was  spliced  efficiently to  exon  2A  in 
both wild-type and lpr mice, but not from exon 2A to exon 
3 in lpr mice, we conclude that the exon 2A sequence is 5' 
of the Etn insertion in Ipr (Fig. l  B). 
Function  In  Vitro.  Such  a  molecule might be  expected 
to act as a soluble competitor for the FasL,  thereby inhibit- 
ing FasL-induced apoptosis.  To  test this hypothesis,  P815 
cells,  which  express  endogenous transmembrane Fas  (Fas 
A), but not Fas B, were transfected with a Fas B-encoding 
cDNA  using  the  eukaryotic  expression  vector  pSRcl- 
72(N.1).  Four clones were selected for study.  Clones 1B7 
and 1D1  had low level expression of Fas B, as determined 
by competitive PCR,  whereas  clones  1D7  and  1Ell  had "~  higher  expression  (data  not  shown).  All  clones 
expressed  Fas A  on  the  cell  surface,  some  more  and some 
less than wild-type P815  (Fig. 2 A). Fas B  was therefore not 
simply interfering with Fas A  expression. 
To  test the biological activity of excess Fas B,  these cells 
were  cultured  overnight on monolayers  of 3T3  fibroblasts 
that had been transfected with FasL  (Fig.  2  B).  After over- 
night  (18  h)  coculture,  viable P815  cells were  counted  by 
nigrosin  exclusion.  Less  than  10%  of the  wild-type  P815 
cells  survived  the  treatment  with  FasL-positive  3T3  cells, 
whereas  20-50%  of clones  1B5  and  1D1,  expressing Fas B 
at low levels,  survived.  Among  the  high  expressing clones 
1D7  and  1Ell,  75-100%  of the  cells survived  FasL  expo- 
sure,  indicating that Fas B  expression  can block Fas-medi- 
Figure 2.  (A) Surface Fas A expression  on P815 cells and transfectants. 
The expression of endogenous Fas on parental P815 cells and Fas B-trans- 
fected  clones  was  examined by FACS  |  with anti-Fas-PE. Transfectants 
continued to express  Fas on the membrane. The order of the labels re- 
flects the level of expression.  Note  that clone 1Ell,  shown in B to be 
completely protected, expressed  the second highest level of Fas. (B) Pro- 
tection from Fas-mediated death by Fas B  expression.  Parental P815  or 
Fas 13 transfectants  were cocultured overnight with FasL or empty-vec- 
tor-transfected 3T3 cells, and the surviving P815 cells counted. Four Fas 
13 transfectants--clones 1B5,  1D1,  1D7,  and 1Ell--were relatively  pro- 
tected from apoptosis  by FasL. Values are mean +  SD of the viable cells 
recovered from overnight cultures  in millions.  Gray bars represent viable 
cells recovered from control 3T3  monolayers and black bars  represent 
cells from FasL-transfected  3T3 monolayers. The effect was due to soluble 
Fas B protein, because supernatant from 1Ell  cells protected wild-type 
P815  cells from FasL-induced apoptosis.  A representative experiment of 
five is shown. Differences  in cell yield from control monolayers were not 
consistent from experiment to experiment and most likely represent dif- 
ferences in the rate of growth within each culture. The protective effect 
ofFas B transfection was consistent in all experiments, however. 
Figure  3.  (A)  Expression  of Fas B-encoding KNA  in vivo.  RNase 
protection was used to examine Fas 13 versus Fas et in 10 p,g of RNA from 
various  tissues. The relative  expression  of Fas 13 was  lower in nonlym- 
phoid than in lymphoid tissues. A  representative experiment of five  is 
shown. Similar results were obtained from poly-A  + IkNA. (B) Expression 
of Fas B-encoding RNA during thymic development. Thymocytes from 
C57B1/6 mice were sorted by FACS |  according to CD4 and CD8 ex- 
pression  or by TCR density.  RNase protection was used to examine ex- 
pression  of Fas 13 versus  Fas et in samples of tkNA from subsets of thy- 
mocytes.  4.0  ￿  106  cells were  used for  each sample.  A  representative 
experiment of three is shown. 
1397  Hughes and Crispe Figure 4.  (A and B) Surface Fas expression in IHL subsets. IHLs were isolated from C57B1/6  mice as described  (20) and stained with anti-TCRI3, anti- 
B220,  and anti-Fas  and examined by FACS  |  in three colors.  The gates shown for TCR13  and B220 expression in Fig. 4 A were used to generate the Fas 
expression histograms shown "in Fig. 4 B. The solid line  represents the B220 + subset,  and the dashed line  represents the B220-  subset.  Unstained cells 
(dotted line) are shown for comparison. (C) Expression of Fas B-encoding RNA in IHL subsets. IHLs were sorted into two populations of TCR13 + cells 
based on B220 expression as shown in Fig. 4 A. RNase protection was used to examine expression of Fas 13 versus Fas ~x in RNA from 0.5  X  106 B220- 
IHLs and 1.5  ￿  106 B220 + IHLs. This expression was compared with that of 4  ￿  106 thymocytes, total  IHLs, LNCs, and splenocytes.  In addition,  Fas 
expression in 5 ~g ofhver RNA was tested. A representative  experiment of three is shown. (D) Quantitation of Fas 13 expression in IHL subsets. Intensity 
of expression of Fas relative  to ",/-actin in subsets of IHLs and controls is shown. Values are mean expression in three experiments; error bars show stan- 
dard deviation.  Because  hepatocytes primarily express 13-actin rather than ~/-actin, quantitation of the total liver RNA sample is not shown. Quantitation 
was performed using a phosphorimager as described  in Materials  and Methods. 
ated apoptosis. The protection is caused by a soluble mate- 
rial,  since supernatant from clone 1Ell  protected parental 
P815  cells  from apoptosis.  We conclude that Fas B  is se- 
creted by the transfected cells as a soluble protein that in- 
hibits apoptosis induced by Fas-FasL interaction. 
Expression In Vivo.  The messages  encoding Fas  A  and 
Fas B were differentially expressed in different cell popula- 
tions.  The expressions of Fas oL and  Fas  13 in RNA from 
various tissues were analyzed by RNase protection (Fig.  3, 
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A  and  B).  Fas  JB was  more abundant  in lymphoid tissues; 
11-20%  of the  Fas  message  in  thymus,  LN,  spleen,  and 
bone marrow, but <5% of the total Fas message from liver, 
kidney, heart, and lung was in the Fas J3 form. Two T  cell 
populations, thymocytes and IHLs, were selected for detailed 
analysis. Thymocyte subsets were tested because thymocytes 
are  Fas  positive  (16,  23),  highly  susceptible  to  apoptosis 
(24-26), and differentially susceptible  to Fas-mediated apop- 
tosis (27-29). Thymocytes were sorted by FACS  |  into sub- sets at different developmental stages based on TCR expres- 
sion or CD4 and CD8 phenotype.  Fas mRNA expression 
was very low in CD4-CD8-  progenitor thymocytes, high 
in  CD4+CD8 +  immature  cells,  and  lower  on  mature 
CD4+CD8 -  and CD8+CD4 -  cells,  following the pattern 
of Fas expression on the membrane (29, 30). The Fas ot/Fas 
13 ratio, however, did not differ among these subsets (Fig.  3 
/3). We conclude that the recently reported exquisite sensi- 
tivity of CD4+CD8 + thymocytes to apoptosis induced by 
Fas  ligation  (27-29)  is  not  caused by differential low  ex- 
pression of Fas B in these cells. 
In contrast to thymocytes, there is a strong case that Fas 
is important in the apoptosis of mature T  cells and that this 
apoptosis occurs in the liver (4, 31). The two major subsets 
of intrahepatic  T  cells  defined  by  B220  expression  ex- 
pressed Fas on the cell membrane at similar density (Fig.  4, 
A and B). These cell subsets had similar overall Fas mRNA 
levels  but  very  different  ratios  of Fas  a  to  Fas  13.  The 
B220+CD4-CD8 -  subset, in which N20% of the cells are 
in the  process of apoptosis (20),  expressed a  high level of 
Fas c~ with a low level of Fas 13. In contrast, the B220- sub- 
set, composed of both CD4 SP and CD8 SP cells (20),  ex- 
pressed high levels of both Fas transcripts (Fig. 4, C and D). 
Because  the  two populations  express a  similar amount  of 
Fas A  on the cell surface, their difference in Fas  13 expres- 
sion probably accounts for their difference in apoptosis. 
Discussion 
While  superantigen-induced  deletion  of mature  CD4 + 
T  cells  results in apoptosis in the lymph nodes  (32),  pep- 
tide-driven deletion of CD8 + T  cells leads to accumulation 
and  apoptosis at  a  specific anatomical site:  the  liver  (31). 
Activated T  cells  express an increased level of Fas  on the 
cell membrane and are susceptible to Fas-induced apoptosis 
(5,  8,  10).  We propose that the liver is the site of activated 
T  cell apoptosis because it is a site in which the T  cells are 
exposed to  FasL.  This implies that all  Fas-positive T  cells 
among the  IHL are vulnerable to  FasL-induced  apoptosis 
unless specifically protected. The CD4 + and CD8 + T  cells 
in  the  liver appear to  be protected  by their  elevated ex- 
pression of Fas B. The function of these cells is unknown; 
their resistance to apoptosis suggests that unlike the B220 + 
CD4-CD8-  cells,  they are  not proceeding along the pe- 
ripheral deletion pathway.  It is possible that,  instead,  they 
are the effectors of deletion. 
A very different splice variant of the human Fas gene has 
been cloned by using PCR from T  cells of a patient with 
systemic  lupus  erythematosus  (33).  This  cDNA  resulted 
from deletion  of the transmembrane region,  leaving a se- 
quence  with  the  potential  to  encode  a  soluble  molecule 
consisting of the extracellular domain direcdy linked to the 
signaling domain (sFas). The structure of sFas is highly un- 
usual for a soluble receptor isoform. Whereas a number of 
other  transmembrane  receptors  (for  example,  IL-7  and 
G-CSF)  generate  soluble  isoforms by splicing  out  of the 
transmembrane region,  such deletions cause frameshifts or 
stop  codons,  as  we  describe  here  for  Fas  B  (3,  34).  An 
ELISA with anti-Fas antibody showed that a form of solu- 
ble Fas was present in the sera of some lupus patients, but 
whether this is in fact transmembrane-deficient sFas, a hu- 
man equivalent of murine Fas B, or simply Fas A shed from 
the  surface of dying cells  remains to  be determined.  The 
expression pattern of transmembrane-deficient sFas in nor- 
mal human T  cells has not yet been defined.  It is possible 
that both humans and mice regulate Fas-mediated apoptosis 
through soluble isoforms but generate these in completely 
different ways. It is also possible that sFas and Fas B exist in 
both species but perform different functions. A recent study 
of mouse  Fas  protein  expression by immunoprecipitation 
showed three molecular species, which may correspond to 
Fas A, Fas B, and sFas (35). 
The  abnormal  Fas  mRNA  species  generated  in  mice 
with  the lpr mutation have the  potential  to  encode  trun- 
cated forms of Fas similar to Fas B  (22).  The insertion of 
the Etn transposon in this mutation leads to frequent splic- 
ing  of RNA  to  a  site just  5'  of the  LTR;  this  generates 
truncated messages that use the Etn poly A addition site and 
can be translated (22).  These aberrant transcripts could in- 
clude exon 2A and generate a protein very similar to Fas B. 
In  preliminary  experiments  by  RNase  protection,  we 
found a high proportion of Fas transcripts with exon 2A in 
lpr  thymus  RNA  (unpublished  data).  Because  lpr  thy- 
mocytes were recently shown to express a very low level of 
Fas protein  (35),  the presence of Fas B-like isoforms may 
contribute  to  the  lpr  phenotype  by  blocking  signaling 
through the few Fas molecules that are expressed. This also 
raises the question whether Fas B-like molecules are over- 
expressed in other mouse strains with spontaneous autoim- 
munity, where they may act to subvert normal apoptosis of 
potentially self-reactive T  cells. 
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